By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit, LinkedIn and follow us on


Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 20,000
Symbol: AMGN

Company News
Coherus Completes Patent Dance Exchange With Amgen (AMGN) For Neulasta Biosimilar 4/25/2017 9:49:34 AM
Sanofi (SNY) And Now Amgen (AMGN)-Backed Science 37 Racks Up Another $29 Million 4/25/2017 7:53:05 AM
Novartis AG (NVS) Expands Global Collaboration With Amgen (AMGN) To Commercialize First-In-Class AMG 334 (Erenumab) Program In Migraine Prevention In The U.S. And Canada 4/25/2017 6:23:22 AM
Amgen (AMGN), Novartis AG (NVS) Expands Migraine Drug Tie-Up 4/25/2017 6:07:36 AM
Amgen (AMGN) Announces Webcast Of 2017 First Quarter Financial Results 4/24/2017 10:27:10 AM
California Life Sciences Institute Names 2017 Winner Of Amgen (AMGN) Bay Area BioGENEius Competition 4/24/2017 9:32:08 AM
Unstoppable Celgene (CELG) to Take Over Amgen (AMGN)'s Former Space in Cambridge 4/21/2017 5:45:59 AM
Amgen (AMGN) Launches Neulasta (Pegfilgrastim) Onpro NARRATIVES 4/19/2017 6:46:18 AM
As Biotech Roars Back, Amgen (AMGN) Remains Dirt Cheap 4/5/2017 7:09:18 AM
Amgen (AMGN) Submits Applications In The US And Europe To Expand Current Indication For XGEVA (Denosumab) To Include Patients With Multiple Myeloma 4/4/2017 8:33:42 AM